Over the past seven years, Claus Moller helped steer Y-mAbs Therapeutics from a secretive Danish biotech startup laser-focused on two pediatric cancer treatments to a Nasdaq-listed company boasting a three-pronged platform of immunotherapies, radiotherapies and companion diagnostics.
But as Y-mAbs gets deeper into commercialization, its longtime CEO is heading out.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,